The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Just sitting back and dreaming TF. Hence the "One day"
Holding over 5 years from an early dabble at around 5 , much reduced now.
Pharmaceutical giant AstraZeneca (AZN) has agreed to buy Nasdaq-listed Fusion Pharmaceuticals (FUSN:NASDAQ) for around $2 billion in cash to boost its cancer portfolio.
BUT, it's already been postponed once ,so what possible influence do you gather that the delay is down to hamas, empty end!
Today 08:17
Everest Global Plc - Investment in UK wine retailer
Everest Global Plc - Investment in UK wine retailer
PR Newswire
LONDON, United Kingdom, July 04
4 July 2023
Everest Global plc
(“Everest” or the “Company”)
Investment in UK wine retailer
Everest has entered into an agreement to provide a loan to Precious Link (UK) Limited (“Precious Link”), a wine retailer, incorporated and registered in England and Wales, located within the Southeast of England.
The loan is for a sum of £200,000, is unsecured and attracts interest at 10 per cent. per annum payable monthly in arrears. The loan is repayable on demand by the Company and is repayable on 5 business days’ notice from Precious Link.
The strategy of the Company has been to develop a group with a focus on food, agriculture and agricultural related products. The Company believes Precious Link operates in a complementary sector and therefore the loan to Precious Link could assist the Company in expanding its activities into the wider food and beverage sector.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).
There is always a 15 minute delay!
Got my lot out of the bottom drawer, interest coming back, slowly but surely.
Can't even get that right!!
I had the voting form from Halifax in the post this week, posted it today.
and there's more
We believe that SCIB1 administration in combination with doublet therapy has the potential to offer greater efficacy than checkpoint inhibitors alone, without increasing toxicity."
Professor Poulam Patel, Chief Investigator, commented: "The treatment landscape for metastatic melanoma patients has changed and most patients in the UK are now treated with ipilimumab/nivolumab doublet therapy. As the Chief Investigator for this combination study, I am delighted to be working with Scancell to determine if the addition of SCIB1 to doublet therapy improves response rates. In addition, the delivery of SCIB1 via a needle-free injection will be welcomed by our healthcare team administering the vaccine."
Chris Cappello, President and CEO, PharmaJet, commented: "We are pleased to be partnering with Scancell as they expand their Phase 2 trial with a needle-free delivery option for patients with advanced melanoma. In addition to increasing patient acceptance, our partners have published results showing superior results to other vaccine delivery systems."
Further information relating to the Company's clinical trials can be found on www.scancell.co.uk and at https://clinicaltrials.gov.
RNS Number : 8802O
Scancell Holdings Plc
15 June 2022
15 June 2022
Scancell Holdings plc
("Scancell" or the "Company")
Phase 2 SCOPE trial of SCIB1 vaccine in metastatic melanoma patients expanded
Additional cohort to test SCIB1 vaccine in combination with checkpoint doublet therapy
Protocol amendment broadens patient population for inclusion in the trial and enables faster recruitment to remain on track to deliver initial efficacy data in 2022
SCIB1 to be delivered using PharmaJet Needle-free Injection System
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces an update to the Phase 2 SCOPE clinical trial being conducted at multiple centres in the UK. Following the approval of a protocol amendment by the Medicines and HealthCare products Regulatory Agency (MHRA), the trial will include a cohort of melanoma patients who will receive SCIB1 plus doublet therapy consisting of ipilimumab (Yervoy®) plus nivolumab (Opdivo®) in addition to the cohort who will receive SCIB1 with pembrolizumab (Keytruda®). The updated protocol also allows all patients to receive the SCIB1 vaccine as a needle-free injection.
SCIB1 is the lead product from the Company's ImmunoBody® immunotherapy platform, which uses the body's immune system to identify, attack and destroy tumours. In a Phase 1/2 clinical trial, 14 out of 16 resected patients (89%) survived for more than 5 years following vaccination with SCIB1. The original Phase 2 study was designed to assess whether the addition of SCIB1 treatment to pembrolizumab results in an improvement in patient outcomes for patients with metastatic disease. The primary objectives of the trial are tumour response rate, progression-free survival and overall survival in patients with advanced melanoma. The amendment to the SCOPE protocol follows changes in the treatment landscape where the current most common treatment for metastatic melanoma patients is a doublet therapy combining two checkpoint inhibitors, ipilimumab and nivolumab.
Under the updated protocol the company will also test the SCIB1 vaccine delivered via needle free injection. To date, SCIB1 has been delivered using electroporation to enhance the uptake and presentation of the DNA vaccine to the immune system and, although electroporation is a proven delivery method, the Company believes that needle-free injection could provide enhanced patient acceptance. The Company is currently using PharmaJet Needle-Free Injector Systems in its COVIDITY trial being carried out in South Africa.
Professor Lindy Durrant, Chief Executive Officer, Scancell, commented: "The approved amendments will expand the patient population eligible to receive SCIB1 and are therefore expected to increase recruitment rates, allowing the study to remain on track to deliver initial efficacy data in 2022. We believe that SCIB1 administrat
10 Billion extra shares!!
IMHO if you're selling to take the profit, sell the 5's
If they know nothing today, they won't tell you today, if they no nothing before the AGM they won't tell you at the AGM.
If they know something in between they will tell you all you NEED to know
Simples!
Still stuck on average of 1.01, and still in the bottom drawer, gathering dust!
Same time line. Mostly the Trent for me
The Australia Stock Exchange is open Monday through Friday from 10:00am to 4:00pm Australian Eastern Daylight Time (GMT+11:00). So, opens in just under 9 hours
It's 1am in Melbourne tuesday!
The AstraZeneca case started like this...
EXCLUSIVE @Reuters - NOVAVAX IS DELAYING SIGNING A CONTRACT TO SUPPLY ITS COVID-19 VACCINE TO THE EU AMID PRODUCTION PROBLEMS - EU OFFICIAL
"The speed of entry into the operational phase, barely two months after government ratification of our entry into Turkey and despite pandemic constraints, nicely demonstrates the ability to move projects forwards at pace in Turkey, a welcome change from the UK."
???